Skip to content

Study · Other design · 2021

5 results

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.

Overgaard RV, Hertz CL, Ingwersen SH, Navarria A, Drucker DJ

Cell reports. Medicine3 Sept 2021Cited by 72 (Europe PMC)

PMID34622228 (opens in a new tab)PMCIDPMC8484505 (opens in a new tab)DOI10.1016/j.xcrm.2021.100387 (opens in a new tab)PepBankPUB-34622228
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanOther designEfficacy outcome

    In people with type 2 diabetes, at typical oral semaglutide exposure the estimated HbA1c response was similar for oral and subcutaneous semaglutide after 6 months.

    In plain wordsIn people with type 2 diabetes, oral and injected semaglutide at the same blood level gave a similar HbA1c fall.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c response at 6 months by semaglutide exposure
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral and subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    HbA1c response
    1.58%
    oral
    HbA1c response
    −1.62%
    subcutaneous

    Source sentences

    Summary
    At typical exposure levels for oral semaglutide, the estimated response is 1.58% (oral) versus -1.62% (subcutaneous) for HbA1c and 3.77% (oral) versus 3.48% (subcutaneous) reduction in body weight relative to baseline after 6 months.
    1 context sentence
    Title · context
    Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.
  2. 02HumanOther designEfficacy outcome

    In people with type 2 diabetes, at typical oral semaglutide exposure the estimated body weight reduction was similar for oral and subcutaneous semaglutide after 6 months.

    In plain wordsIn people with type 2 diabetes, oral and injected semaglutide at the same blood level gave a similar weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight reduction at 6 months by semaglutide exposure
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral and subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Body weight reduction
    3.77%
    oral
    Body weight reduction
    3.48%
    subcutaneous

    Source sentences

    Summary
    At typical exposure levels for oral semaglutide, the estimated response is 1.58% (oral) versus -1.62% (subcutaneous) for HbA1c and 3.77% (oral) versus 3.48% (subcutaneous) reduction in body weight relative to baseline after 6 months.
    1 context sentence
    Title · context
    Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.
  3. 03HumanOther designEfficacy outcome

    In people with type 2 diabetes, exposure-response relationships for biomarkers of cardiovascular risk were nearly identical for oral and injectable semaglutide.

    In plain wordsIn people with type 2 diabetes, oral and injected semaglutide showed nearly the same link between blood level and heart-risk markers.

    Peptide
    Semaglutide
    Outcome
    No significant changeBiomarkers of cardiovascular risk by semaglutide exposure
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · oral and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    We demonstrate that nearly identical exposure-response pharmacodynamic relationships are determined by plasma semaglutide levels achieved through oral versus injectable administration for changes in HbA1c, body weight, biomarkers of cardiovascular risk, and AEs such as nausea and vomiting.
    1 context sentence
    Title · context
    Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.
  4. 04HumanOther designSafety outcome

    In people with type 2 diabetes, exposure-response relationships for nausea and vomiting were nearly identical for oral and injectable semaglutide.

    In plain wordsIn people with type 2 diabetes, oral and injected semaglutide showed nearly the same link between blood level and nausea or vomiting.

    Peptide
    Semaglutide
    Outcome
    No significant changeNausea and vomiting by semaglutide exposure
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · oral and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    We demonstrate that nearly identical exposure-response pharmacodynamic relationships are determined by plasma semaglutide levels achieved through oral versus injectable administration for changes in HbA1c, body weight, biomarkers of cardiovascular risk, and AEs such as nausea and vomiting.
    1 context sentence
    Title · context
    Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.
  5. 05HumanOther designPharmacokinetics

    In people with type 2 diabetes, increased body weight was the most important variable associated with reduced semaglutide exposure for both formulations.

    In plain wordsIn people with type 2 diabetes, higher body weight was linked to lower semaglutide blood levels for both oral and injected forms.

    Peptide
    Semaglutide
    Outcome
    DecreaseSemaglutide exposure and body weight
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oral and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Increased body weight is the most important variable associated with reduced semaglutide exposure for both formulations.
    1 context sentence
    Title · context
    Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.